Showing results (11-20 of 20) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 20 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 9, 2006
Y179C, F486L and N550H are BRCA1 variants that may be associated with breast cancer in a Sicilian family: results of a 5-year GOIM (Gruppo Oncologico dell'Italia Meridionale) prospective studyC Augello, L Bruno, V Bazan, et al.
Cancer|July 24, 2001
DNA aneuploidy and high proliferative activity but not K-ras-2 mutations as independent predictors of clinical outcome in operable gastric carcinoma: results of a 5-year Gruppo Oncologico dell'Italia Meridonale (GDIM) prospective studyA Russo, V Bazan, M Migliavacca, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 9, 2006
Molecular detection of TP53, Ki-Ras and p16INK4A promoter methylation in plasma of patients with colorectal cancer and its association with prognosis. Results of a 3-year GOIM (Gruppo Oncologico dell'Italia Meridionale) prospective studyV Bazan, L Bruno, C Augello, et al.
Journal of Cancer Research and Clinical Oncology|December 11, 2002
DNA ploidy and S-phase fraction, but not p53 or NM23-H1 expression, predict outcome in colorectal cancer patients. Result of a 5-year prospective studyV Bazan, M Migliavacca, I Zanna, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 9, 2006
Significance of P16INK4A hypermethylation gene in primary head/neck and colorectal tumors: it is a specific tissue event? Results of a 3-year GOIM (Gruppo Oncologico dell'Italia Meridionale) prospective studyV Agnese, S Corsale, V Calò, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 9, 2006
Detection and quantification of mammaglobin in the blood of breast cancer patients: can it be useful as a potential clinical marker? Preliminary results of a GOIM (Gruppo Oncologico dell'Italia Meridionale) prospective studyG Gargano, V Agnese, V Calò, et al.
Breast (Edinburgh, Scotland)|July 17, 2017
Efficacy and safety of Everolimus and Exemestane in hormone-receptor positive (HR+) human-epidermal-growth-factor negative (HER2-) advanced breast cancer patients: New insights beyond clinical trials. The EVA studyM E Cazzaniga, M Airoldi, V Arcangeli, et al.
Breast (Edinburgh, Scotland)|August 31, 2019
Metronomic chemotherapy for advanced breast cancer patients in the real world practice: Final results of the VICTOR-6 studyM E Cazzaniga, G Pinotti, E Montagna, et al.
Scientific Reports|July 28, 2023
Final results of the real-life observational VICTOR-6 study on metronomic chemotherapy in elderly metastatic breast cancer (MBC) patientsB Trevisan, F F Pepe, I Vallini, et al.
Breast Cancer Research and Treatment|September 21, 2021
Metronomic chemotherapy (mCHT) in metastatic triple-negative breast cancer (TNBC) patients: results of the VICTOR-6 studyM E Cazzaniga, I Vallini, E Montagna, et al.
Pageof 2